Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Total Valuation
Soleno Therapeutics has a market cap or net worth of $2.10B. The enterprise value is $2.03B.
Market Cap$2.10B
Enterprise Value$2.03B
Share Statistics
Soleno Therapeutics has 51,624,386 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,624,386
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Soleno Therapeutics’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 2.97%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)2.97%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee1.66M
Profits Per Employee181.65K
Employee Count115
Asset Turnover0.34
Inventory Turnover0.18
Valuation Ratios
The current PE Ratio of Soleno Therapeutics is 117.9. Soleno Therapeutics’s PEG ratio is -1.08.
PE Ratio117.9
PS Ratio12.93
PB Ratio5.47
Price to Fair Value5.47
Price to FCF52.69
Price to Operating Cash Flow44.20
PEG Ratio-1.08
Income Statement
In the last 12 months, Soleno Therapeutics had revenue of 190.41M and earned 20.89M in profits. Earnings per share was 0.41.
Revenue190.41M
Gross Profit187.71M
Operating Income14.95M
Pretax Income20.89M
Net Income20.89M
EBITDA28.38M
Earnings Per Share (EPS)0.41
Cash Flow
In the last 12 months, operating cash flow was 46.98M and capital expenditures -73.00K, giving a free cash flow of 46.90M billion.
Operating Cash Flow46.98M
Free Cash Flow46.90M
Free Cash Flow per Share0.91
Dividends & Yields
Soleno Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-13.04%
50-Day Moving Average41.65
200-Day Moving Average60.97
Relative Strength Index (RSI)52.09
Average Volume (3m)1.49M
Important Dates
Soleno Therapeutics upcoming earnings date is May 12, 2026, TBA (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Soleno Therapeutics as a current ratio of 5.80, with Debt / Equity ratio of 0.60%
Current Ratio5.80
Quick Ratio5.55
Debt to Market Cap<0.01
Net Debt to EBITDA-2.38
Interest Coverage Ratio2.73
Taxes
In the past 12 months, Soleno Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Soleno Therapeutics EV to EBITDA ratio is 84.37, with an EV/FCF ratio of 51.25.
EV to Sales12.58
EV to EBITDA84.37
EV to Free Cash Flow51.25
EV to Operating Cash Flow51.17
Balance Sheet
Soleno Therapeutics has $305.47M in cash and marketable securities with $2.69M in debt, giving a net cash position of $302.78M billion.
Cash & Marketable Securities$305.47M
Total Debt$2.69M
Net Cash$302.78M
Net Cash Per Share$5.87
Tangible Book Value Per Share$8.37
Margins
Gross margin is 98.58%, with operating margin of 7.85%, and net profit margin of 10.97%.
Gross Margin98.58%
Operating Margin7.85%
Pretax Margin10.97%
Net Profit Margin10.97%
EBITDA Margin14.91%
EBIT Margin13.85%
Analyst Forecast
The average price target for Soleno Therapeutics is $103.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$103.20
Price Target Upside154.12% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast44.84%